Showing 121 - 140 results of 25,616 for search '(( significant cases based ) OR ( significant ((fold decrease) OR (point decrease)) ))', query time: 1.11s Refine Results
  1. 121

    The base case analysis. by Wenwang Lang (20293527)

    Published 2025
    “…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”
  2. 122

    Base-case results. by Shuo Kang (1306860)

    Published 2025
    “…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”
  3. 123
  4. 124
  5. 125
  6. 126
  7. 127

    Base-case results. by Mingxi Xie (19812594)

    Published 2024
    “…The model time-frame was one-year. Base-case analysis and sensitivity analysis were performed. …”
  8. 128

    Base-case analysis. by Akiko Kowada (14659965)

    Published 2023
    “…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …”
  9. 129

    <i>Kdm6a</i> conditional KO mice have decreased repopulating potential in serial competitive transplantation assays. by Ling Tian (107492)

    Published 2021
    “…(E) Quantification of donor cell chimerism of HSCs in BM by flow cytometry 18 weeks after secondary transplantation. Significant differences in the chimerism of SLAM cells compared to whole BM were found in KO-F mice (55.2-fold increase in CD45.2<sup>+</sup> KO-F SLAM cells as compared to CD45.2<sup>+</sup> cells in the whole BM, p = 0.0163) and KO-M mice (11.31-fold increase in CD45.2<sup>+</sup> KO-M SLAM cells as compared to CD45.2<sup>+</sup> cells in the whole BM, p = 0.0010). …”
  10. 130
  11. 131
  12. 132
  13. 133
  14. 134
  15. 135
  16. 136
  17. 137
  18. 138
  19. 139
  20. 140